Cornerstone Planning Group’s Neurocrine Biosciences NBIX Stock Holding History

Cornerstone Planning Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-10	Closed	-$1.73K	–	1131
2026 Q2	$1.73K	Hold	10	–	–	﹤0.01%	1364
2026 Q1	$1.35K	Buy	10 +3	+43%	+$398	﹤0.01%	1379
2025 Q4	$943	Sell	7 -1	-13%	-$145	﹤0.01%	1365
2025 Q3	$358	Buy	8 +5	+167%	+$677	﹤0.01%	1558
2025 Q2	$385	Hold	3	–	–	﹤0.01%	1373
2025 Q1	$310	Sell	3 -13	-81%	-$1.65K	﹤0.01%	1403
2024 Q4	$2.37K	Buy	+16	New	+$1.98K	﹤0.01%	749
2023 Q3	–	Sell	-13	Closed	-$1.23K	–	1277
2023 Q2	$1.23K	Buy	+13	New	+$1.27K	﹤0.01%	1299
2022 Q4	$1.43K	Buy	+13	New	+$1.52K	﹤0.01%	1280

Other funds holding NBIX

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

PKO BP Bankowy Universal Pension Society Warsaw, Poland $340M AUM 228.33% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Cornerstone Planning Group's NBIX Position: Q3 2026 in Review

Cornerstone Planning Group sold out of Neurocrine Biosciences (NBIX) in Q3 2026, closing a stake of 10 shares — an estimated $1.73K sold.

Cornerstone Planning Group first reported a position in NBIX in Q4 2022 and held it in 9 quarters. The position peaked at $2.37K in Q4 2024. 143 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

Cornerstone Planning Group reported no remaining Neurocrine Biosciences position as of Q3 2026 after selling out during the quarter.
Cornerstone Planning Group sold 10 Neurocrine Biosciences shares in Q3 2026, an estimated $1.73K.
Cornerstone Planning Group first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 9 quarters.
Cornerstone Planning Group's Neurocrine Biosciences position peaked at $2.37K in Q4 2024.
143 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Cornerstone Planning Group's 13F filing for Q3 2026, filed 16 Oct 2026.